---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-003747"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:56:50.280664+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports Q3 2021 net loss $11.3M; FA program on track for H1 2022

## Summary
- Net loss $11.3M for Q3 2021; R&D expenses $8.5M, G&A $2.8M.
- Cash, cash equivalents and securities total $393.7M as of Sept 30, 2021.
- FA GeneTAC candidate on track for Phase 1 initiation in H1 2022; topline data expected in 2022.
- DM1 program: preclinical data show near-complete resolution of foci; clinical start planned for 2023.
- Company to present at Piper Healthcare Conference Nov 30 – Dec 2, 2021.

## SEC filing metadata
- accession: 0000950170-21-003747
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/0000950170-21-003747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/dsgn-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-003747
- JSON: https://secwatch.observer/filing/0000950170-21-003747.json
- Plain text: https://secwatch.observer/filing/0000950170-21-003747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.